Epsilon Healthcare Limited (AU:EPN)
ASX:EPN
Want to see AU:EPN full AI Analyst Report?
EPN Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.04
Previous CloseN/A
Volume222.34K
Average Volume (3M)0.00
Market Cap
AU$7.78M
Enterprise ValueAU$21.70M
Total Cash (Recent Filing)AU$242.86K
Total Debt (Recent Filing)AU$14.16M
Price to Earnings (P/E)―
Beta-0.21
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding389,104,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.19
Price to Sales (P/S)1.33
P/FCF Ratio-3.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manufacturing & Regulatory ComplianceOwning cGMP-compliant extraction and manufacturing facilities is a durable competitive advantage in medicinal cannabis. It enables long-term supply to pharmaceutical and healthcare customers, supports regulatory approvals, and allows higher-margin contract and private-label manufacturing, strengthening sustainable revenue channels.
Revenue RecoveryA ~53% revenue rebound in 2025 signals returning market demand and traction for products. If sustained, a larger revenue base can unlock operating leverage, improve fixed-cost absorption in manufacturing, and provide runway to invest in product development or distribution expansion, supporting medium-term stability.
Business DiversificationOffering private-label manufacturing and operating across pharmaceutical, biotech and healthcare channels diversifies revenue sources and customer mix. This structural diversification reduces dependence on a single product or channel and supports steadier cash flows from B2B contracts over multiple quarters.
Bears Say
Negative Cash GenerationConsistent negative operating and free cash flow indicates the business consumes cash to run operations, forcing reliance on external funding or equity. Over months this erodes runway, limits ability to capitalize on demand recovery, and raises refinancing and dilution risk if leverage rises.
High And Rising LeverageDebt-to-equity of ~4.7x reflects materially higher leverage after equity erosion. Elevated leverage constrains strategic flexibility, increases interest and covenant risk, and makes the company vulnerable to funding stress; it weakens resilience to operational setbacks over the medium term.
Persistent Loss-MakingDespite revenue growth and positive gross profit, operating and net margins remain deeply negative (~-22%). Persistent losses reduce retained capital, produce negative ROE, and mean the company has not yet demonstrated sustainable earnings power necessary to self-fund growth or restore equity strength.
Epsilon Healthcare Limited News
EPN FAQ
What was Epsilon Healthcare Limited’s price range in the past 12 months?
Epsilon Healthcare Limited lowest share price was AU$0.02 and its highest was AU$0.04 in the past 12 months.
What is Epsilon Healthcare Limited’s market cap?
Epsilon Healthcare Limited’s market cap is AU$7.78M.
When is Epsilon Healthcare Limited’s upcoming earnings report date?
Epsilon Healthcare Limited’s upcoming earnings report date is Sep 02, 2026 which is in 121 days.
How were Epsilon Healthcare Limited’s earnings last quarter?
Epsilon Healthcare Limited released its earnings results on Feb 27, 2026. The company reported AU$0.002 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.002.
Is Epsilon Healthcare Limited overvalued?
According to Wall Street analysts Epsilon Healthcare Limited’s price is currently Overvalued.
Does Epsilon Healthcare Limited pay dividends?
Epsilon Healthcare Limited does not currently pay dividends.
What is Epsilon Healthcare Limited’s EPS estimate?
Epsilon Healthcare Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Epsilon Healthcare Limited have?
Epsilon Healthcare Limited has 389,104,000 shares outstanding.
What happened to Epsilon Healthcare Limited’s price movement after its last earnings report?
Epsilon Healthcare Limited reported an EPS of AU$0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Epsilon Healthcare Limited?
Currently, no hedge funds are holding shares in AU:EPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Epsilon Healthcare Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
404.65%
Trailing 12-Months
Asset Growth
84.04%
Trailing 12-Months
Company Description
Epsilon Healthcare Limited
Epsilon Healthcare Limited operates as a healthcare and pharmaceuticals company primarily in Australia and Canada. It engages in the manufacture and distribution of hydroponics equipment, materials, and nutrients; and development and delivery of medicinal cannabis, as well as provides turnkey cannabis cultivation solutions. The company was formerly known as THC Global Group Limited and changed its name to Epsilon Healthcare Limited in February 2021. Epsilon Healthcare Limited was incorporated in 2016 and is based in Sydney, Australia.
Technical Analysis
Vita Life Sciences Limited
―
Little Green Pharma Ltd.
―
Medical Developments International Limited
―
Althea Group Holdings Ltd.
―
IDT Australia Limited
―
Options Prices
Currently, No data available
---